PEN - Penumbra, Inc.
| Previous Close | 147.81 |
| Open | 148.14 |
| Bid | 147.49 x 1100 |
| Ask | 147.29 x 800 |
| Day's Range | 146.08 - 151.13 |
| 52 Week Range | 110.84 - 185.70 |
| Volume | 5,203,648 |
| Avg. Volume | 509,455 |
| Market Cap | 5.146B |
| Beta (3Y Monthly) | 0.96 |
| PE Ratio (TTM) | 358.98 |
| EPS (TTM) | 0.41 |
| Earnings Date | Aug 7, 2017 - Aug 11, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 174.33 |
- GuruFocus.com
Penumbra Inc (PEN) Chairman and CEO Adam Elsesser Sold $1.2 million of Shares
Chairman and CEO of Penumbra Inc (30-Year Financial, Insider Trades) Adam Elsesser (insider trades) sold 8,000 shares of PEN on 09/11/2019 at an average price of $144.67 a share. Continue reading...
- PR Newswire
S&P Dow Jones Indices Announces Nine Companies Set to Join S&P MidCap 400; Ten Companies to Join S&P SmallCap 600
NEW YORK , Sept. 6, 2019 /PRNewswire/ -- S&P Dow Jones Indices will make the following index adjustments to the S&P MidCap 400 and S&P SmallCap 600 to ensure each index more appropriately represents its ...
- Thomson Reuters StreetEvents
Edited Transcript of PEN earnings conference call or presentation 6-Aug-19 8:30pm GMT
Q2 2019 Penumbra Inc Earnings Call
- PR Newswire
Sri Kosaraju Promoted to President and CFO of Penumbra
ALAMEDA, Calif., Aug. 29, 2019 /PRNewswire/ -- Penumbra, Inc. (PEN), a global healthcare company focused on innovative therapies, today announced the promotion of Sri Kosaraju to President, in addition to his current responsibilities as CFO of Penumbra. Kosaraju joined Penumbra as chief financial officer and head of strategy in 2015. "This promotion formalizes the additional responsibilities that Sri has taken on over the recent past and allows us greater capacity to focus on our growing opportunities here at Penumbra.
- PR Newswire
Penumbra, Inc. to Present at the Morgan Stanley 17th Annual Global Healthcare Conference
ALAMEDA, Calif. , Aug. 27, 2019 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN ) today announced that its management team is scheduled to present at the Morgan Stanley 17 th Annual Global Healthcare Conference ...
- Simply Wall St.
Why We’re Not Keen On Penumbra, Inc.’s (NYSE:PEN) 8.2% Return On Capital
Today we'll look at Penumbra, Inc. (NYSE:PEN) and reflect on its potential as an investment. Specifically, we're going...
- GuruFocus.com
Penumbra Inc (PEN) EVP and Chief Business Officer Lynn Rothman Sold $723,300 of Shares
EVP and Chief Business Officer of Penumbra Inc (30-Year Financial, Insider Trades) Lynn Rothman (insider trades) sold 5,000 shares of PEN on 08/19/2019 at an average price of $144.66 a share. Continue reading...
- GuruFocus.com
Penumbra Inc (PEN) Chairman, CEO and President Adam Elsesser Sold $1.2 million of Shares
Chairman, CEO and President of Penumbra Inc (30-Year Financial, Insider Trades) Adam Elsesser (insider trades) sold 8,000 shares of PEN on 08/12/2019 at an average price of $149.24 a share. Continue reading...
Motley FoolPenumbra, Inc. (PEN) Q2 2019 Earnings Call Transcript
PEN earnings call for the period ending June 30, 2019.
- Zacks
Penumbra (PEN) Surpasses Q2 Earnings and Revenue Estimates
Penumbra (PEN) delivered earnings and revenue surprises of 28.57% and 2.25%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- PR Newswire
Penumbra, Inc. Reports Second Quarter 2019 Financial Results
ALAMEDA, Calif. , Aug. 6, 2019 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the second quarter ended June ...
- GuruFocus.com
Penumbra Inc (PEN) CFO and Head of Strategy Sridhar Kosaraju Sold $846,800 of Shares
CFO and Head of Strategy of Penumbra Inc (30-Year Financial, Insider Trades) Sridhar Kosaraju (insider trades) sold 5,000 shares of PEN on 08/01/2019 at an average price of $169.36 a share. Continue reading...
- Schaeffer's Investment Research
Spruce Point: This Stock Could Sink 55%
The research firm issued a "strong sell" opinion on the surgical instrument maker
- Zacks
Penumbra (PEN) Reports Next Week: Wall Street Expects Earnings Growth
Penumbra (PEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
Here's Why Investors Should Consider Cerner (CERN) Stock
For the second quarter, Cerner (CERN) expects revenues between $1.41 billion and $1.46 billion.
- PR Newswire
Penumbra, Inc. to Present at the Canaccord Genuity 39th Annual Growth Conference
ALAMEDA, Calif. , July 17, 2019 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Canaccord Genuity 39th Annual Growth Conference in Boston, ...
- Zacks
Henry Schein Closes Acquisition of Elite Computer Italia
The Elite Computer acquisition marks Henry Schein's (HSIC) foray into the Italian dental practice management software market.
- Zacks
NextGen Inks Deal With Appriss Health, Boosts EHR System
NextGen (NXGN) integrates Appriss Health prescription monitoring and tracking analytics into NextGen Office that is likely to enhance the former's EHR system.
- PR Newswire
Penumbra, Inc. Schedules Second Quarter 2019 Earnings Release and Conference Call for August 6, 2019
ALAMEDA, Calif. , July 16, 2019 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the second quarter 2019 after market close ...
- Zacks
Intuitive Surgical to Boost da Vinci Platform With Buyout
Intuitive Surgical's (ISRG) acquisition of Scholly Fiberoptic's robotic endoscope business to likely boost the acquirer's da Vinci Surgical system.
- Zacks
Chemed's Roto-Rooter & VITAS Robust, Acuity Mix Shift Weak
Chemed's (CHE) VITAS shows higher adoption via an expanded average daily census. Also, the Roto-Rooter's business grows on the back of strong core plumbing and drain cleaning service segments.
- Zacks
Masimo (MASI) Hits a 52-Week High on Solid Growth Drivers
Masimo (MASI) gains from expansion of product portfolio and recent regulatory approvals.
- Zacks
Abbott MitraClip G4 Gets FDA Nod, Valve Repair Options Expand
The FDA approval for MitraClip G4 is expected to enhance Abbott's (ABT) cardiac treatment portfolio.
